Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis

Journal of the American Society of Nephrology

Volumn 29, Issue 7, 2018, Pages 1979-1991

  Leong, Sheldon C ^a   Sao, Justin N ^a   Taussig, Abigail ^a   Plummer, Natalie S ^a   Meyer, Timothy W ^a   Sirich, Tammy L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE DERIVATIVE; HIPPURIC ACID; INDICAN; PARA CRESOL; PHENYLACETYLGLUTAMINE; UNCLASSIFIED DRUG; 4-CRESOL SULFATE; CRESOL; GLUTAMINE; HIPPURIC ACID DERIVATIVE; SULFATE; UREA;

AGED; ANURIA; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SOLUTE; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CRESOLS; FEMALE; GLUTAMINE; HIPPURATES; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SULFURIC ACID ESTERS; UREA;

EID: 85049405534     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2018010081     Document Type: Article

References (40)

1. Rhee CM, Ghahremani-Ghajar M, Obi Y, Kalantar-Zadeh K: Incremental and infrequent hemodialysis: A new paradigm for both dialysis initiation and conservative management. Panminerva Med 59: 188–196, 2017
2. Tangvoraphonkchai K, Davenport A: Increasing haemodialytic clearances as residual renal function declines: An incremental approach. Blood Purif 44: 217–226, 2017
3. Davenport A: Will incremental hemodialysis preserve residual function and improve patient survival? Semin Dial 28: 16–19, 2015
4. Ghahremani-Ghajar M, Rojas-Bautista V, Lau WL, Pahl M, Hernandez M, Jin A, et al.: Incremental hemodialysis: The university of California irvine experience. Semin Dial 30: 262–269, 2017
5. Basile C, Casino FG, Kalantar-Zadeh K: Is incremental hemodialysis ready to return on the scene? From empiricism to kinetic modelling. J Nephrol 30: 521–529, 2017
6. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158–2162, 2001
7. Golper TA: Incremental dialysis: Review of recent literature. Curr Opin Nephrol Hypertens 26: 543–547, 2017
8. Obi Y, Eriguchi R, Ou SM, Rhee CM, Kalantar-Zadeh K: What is known and unknown about twice-weekly hemodialysis. Blood Purif 40: 298–305, 2015
9. Mathew A, Obi Y, Rhee CM, Chen JL, Shah G, Lau WL, et al.: Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis. Kidney Int 90: 1071–1079, 2016
10. Bargman JM, Golper TA: The importance of residual renal function for patients on dialysis. Nephrol Dial Transplant 20: 671–673, 2005
11. Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K: Preservation of residual kidney function in hemodialysis patients: Reviving an old concept. Kidney Int 90: 262–271, 2016
12. Toth-Manikowski SM, Shafi T: Hemodialysis prescription for incident patients: Twice seems nice, but is it incremental? Am J Kidney Dis 68: 180–183, 2016
13. Lowenstein J, Grantham JJ: Residual renal function: A paradigm shift. Kidney Int 91: 561–565, 2017
14. Suchy-Dicey AM, Laha T, Hoofnagle A, Newitt R, Sirich TL, Meyer TW, et al.: Tubular secretion in CKD. J Am Soc Nephrol 27: 2148–2155, 2016
15. Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V: Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol 10: 2039–2049, 2015
16. Sirich TL, Funk BA, Plummer NS, Hostetter TH, Meyer TW: Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 25: 615–622, 2014
17. Sirich TL, Aronov PA, Plummer NS, Hostetter TH, Meyer TW: Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int 84: 585–590, 2013
18. Marquez IO, Tambra S, Luo FY, Li Y, Plummer NS, Hostetter TH, et al.: Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 6: 290–296, 2011
19. National Kidney Foundation: KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66: 884–930, 2015
20. Daugirdas JT, Depner TA, Greene T, Silisteanu P: Solute-solver: A web-based tool for modeling urea kinetics for a broad range of hemodialysis schedules in multiple patients. Am J Kidney Dis 54: 798–809, 2009
21. Chin AI, Depner TA, Daugirdas JT: Assessing the adequacy of small solute clearance for various dialysis modalities, with inclusion of residual native kidney function. Semin Dial 30: 235–240, 2017
22. Gotch FA: The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 13[Suppl 6]: 10–14, 1998
23. Hemodialysis Adequacy 2006 Work Group: Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48[Suppl 1]: S2–S90, 2006
24. Kalantar-Zadeh K, Unruh M, Zager PG, Kovesdy CP, Bargman JM, Chen J, et al.: Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 64: 181–186, 2014
25. Obi Y, Streja E, Rhee CM, Ravel V, Amin AN, Cupisti A, et al.: Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: A cohort study. Am J Kidney Dis 68: 256–265, 2016
26. Kalantar-Zadeh K, Crowley ST, Beddhu S, Chen JLT, Daugirdas JT, Goldfarb DS, et al.: Renal replacement therapy and incremental hemodialysis for veterans with advanced chronic kidney disease. Semin Dial 30: 251–261, 2017
27. Scribner BH, Cole JJ, Ahmad S, Blagg CR: Why thrice weekly dialysis? Hemodial Int 8: 188–192, 2004
28. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription of patient morbidity: Report from the National Cooperative Dialysis Study. N Engl J Med 305: 1176–1181, 1981
29. Burton BT: Adequacy of dialysis. Introduction: Purpose of the conference. Kidney Int 2 [Suppl 1]: 1975
30. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28: 526–534, 1985
31. Saran R, Li Y, Robinson B, et al.: US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 67: S1–S434, 2016
32. Schneditz D, Platzer D, Daugirdas JT: A diffusion-adjusted regional blood flow model to predict solute kinetics during haemodialysis. Nephrol Dial Transplant 24: 2218–2224, 2009
33. Roumelioti ME, Nolin T, Unruh ML, Argyropoulos C: Revisiting the middle molecule hypothesis of uremic toxicity: A systematic review of beta 2 microglobulin population kinetics and large scale modeling of hemodialysis trials in silico. PLoS One 11: e0153157, 2016
34. Odell RA, Slowiaczek P, Moran JE, Schindhelm K: Beta 2-microglobulin kinetics in end-stage renal failure. Kidney Int 39: 909–919, 1991
35. Ward RA, Greene T, Hartmann B, Samtleben W: Resistance to inter-compartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 69: 1431–1437, 2006
36. Cheung KWK, Hsueh CH, Zhao P, Meyer TW, Zhang L, Huang SM, et al.: The effect of uremic solutes on the organic cation transporter 2. J Pharm Sci 106: 2551–2557, 2017
37. Hsueh CH, Yoshida K, Zhao P, Meyer TW, Zhang L, Huang SM, et al.: Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. Mol Pharm 13: 3130–3140, 2016
38. Rivara MB, Zelnick LR, Hoofnagle AN, Newitt R, Tracy RP, Kratz M, et al.: Diurnal and long-term variation in plasma concentrations and renal clearances of circulating markers of kidney proximal tubular secretion. Clin Chem 63: 915–923, 2017
39. Casino FG, Basile C: How to set the stage for a full-fledged clinical trial testing ‘incremental haemodialysis’ [published online ahead of print July 21, 2017]. Nephrol Dial Transplant doi: 10.1093/ndt/gfx225
40. Casino FG, Basile C: The variable target model: A paradigm shift in the incremental haemodialysis prescription. Nephrol Dial Transplant 32: 182–190, 2017